195 related articles for article (PubMed ID: 2460585)
1. Synthetic env gp41 peptide as a sensitive and specific diagnostic reagent in different stages of human immunodeficiency virus type 1 infection.
Närvänen A; Korkolainen M; Suni J; Korpela J; Kontio S; Partanen P; Vaheri A; Huhtala ML
J Med Virol; 1988 Oct; 26(2):111-8. PubMed ID: 2460585
[TBL] [Abstract][Full Text] [Related]
2. Reliable confirmation of antibodies to human immunodeficiency virus type 1 (HIV-1) with an enzyme-linked immunoassay using recombinant antigens derived from the HIV-1 gag, pol, and env genes.
Ng VL; Chiang CS; Debouck C; McGrath MS; Grove TH; Mills J
J Clin Microbiol; 1989 May; 27(5):977-82. PubMed ID: 2787334
[TBL] [Abstract][Full Text] [Related]
3. Presence of antibodies to a putatively immunosuppressive part of human immunodeficiency virus (HIV) envelope glycoprotein gp41 is strongly associated with health among HIV-positive subjects.
Klasse PJ; Pipkorn R; Blomberg J
Proc Natl Acad Sci U S A; 1988 Jul; 85(14):5225-9. PubMed ID: 2455899
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity and specificity of anti-HIV ELISA employing recombinant (p24, p66, gp120) and synthetic (gp41) viral antigenic peptides.
Filice G; Soldini L; Orsolini P; Razzini E; Gulminetti R; Campisi D; Chiapparoli L; Cattaneo E; Achilli G
Microbiologica; 1991 Jul; 14(3):185-94. PubMed ID: 1717811
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of gp41 antigens by enzyme-linked immunosorbent assays for detecting antibodies to human immunodeficiency virus type 1.
Zweig M; Bladen SV; Dubois GC; Samuel KP; Showalter SD; Papas TS
AIDS Res Hum Retroviruses; 1988 Dec; 4(6):487-92. PubMed ID: 3265329
[TBL] [Abstract][Full Text] [Related]
6. Site-directed enzyme-linked immunosorbent assay with a synthetic simian immunodeficiency virus SIVmac peptide identifying antibodies against the HIV-2 transmembrane glycoprotein.
Norrby E; Chiodi F; Whalley A; Parks E; Nauclér A; Costa CM; Torstensson R; Biberfeld G
AIDS; 1989 Jan; 3(1):17-20. PubMed ID: 2469436
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a new dot blot assay for confirmation of human immunodeficiency virus type 1 and 2 infections using recombinant p24, gp41, gp120 and gp36 antigens.
Ravanshad M; Sabahi F; Mahboudi F; Kazemnejad A
Saudi Med J; 2006 Jan; 27(1):31-6. PubMed ID: 16432590
[TBL] [Abstract][Full Text] [Related]
8. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.
Viscidi R; Ellerbeck E; Garrison L; Midthun K; Clements ML; Clayman B; Fernie B; Smith G
AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1251-6. PubMed ID: 1706607
[TBL] [Abstract][Full Text] [Related]
9. Use of a conserved immunodominant epitope of HIV surface glycoprotein gp41 in the detection of early antibodies.
Cumming SA; McPhee DA; Maskill WJ; Kemp BE; Doherty RR; Gust ID
AIDS; 1990 Jan; 4(1):83-6. PubMed ID: 1690552
[TBL] [Abstract][Full Text] [Related]
10. Antibody to a synthetic oligopeptide in subjects at risk for human immunodeficiency virus infection.
Smith RS; Naso RB; Rosen J; Whalley A; Hom YL; Hoey K; Kennedy CJ; McCutchan JA; Spector SA; Richman DD
J Clin Microbiol; 1987 Aug; 25(8):1498-504. PubMed ID: 3476491
[TBL] [Abstract][Full Text] [Related]
11. Site-directed ELISA with synthetic peptides representing the HIV transmembrane glycoprotein.
Chiodi F; von Gegerfeldt A; Albert J; Fenyö EM; Gaines H; von Sydow M; Biberfeld G; Parks E; Norrby E
J Med Virol; 1987 Sep; 23(1):1-9. PubMed ID: 3500271
[TBL] [Abstract][Full Text] [Related]
12. Monitoring human immunodeficiency virus type 1-infected patients by ratio of antibodies to gp41 and p24.
Schmidt G; Amiraian K; Frey H; Wethers J; Stevens RW; Berns DS
J Clin Microbiol; 1989 May; 27(5):843-8. PubMed ID: 2501350
[TBL] [Abstract][Full Text] [Related]
13. Differential IgG subclass responses to epitopes in transmembrane protein of HIV-1.
Klasse PJ; Blomberg J; Pipkorn R
Viral Immunol; 1990; 3(2):89-98. PubMed ID: 1694431
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and persistence of antibody titers to recombinant HIV-1 core and matrix proteins in HIV-1 infection.
Janvier B; Mallet F; Cheynet V; Dalbon P; Vernet G; Besnier JM; Choutet P; Goudeau A; Mandrand B; Barin F
J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):898-903. PubMed ID: 8315575
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic significance of antibodies to HIV nuclear proteins in patients with the lymphadenopathy syndrome].
Schulte C; Meurer M; Fröschl M
Hautarzt; 1988 Jan; 39(1):45-8. PubMed ID: 3162727
[TBL] [Abstract][Full Text] [Related]
16. [Strip immunoblot assay (SIA) with recombinant antigens and synthetic peptide for detection of anti HIV-1 and HIV-2 antibodies].
Deguchi M; Yamashita N; Kagita M; Asari S; Yanagihara T
Kansenshogaku Zasshi; 2001 May; 75(5):371-81. PubMed ID: 11424486
[TBL] [Abstract][Full Text] [Related]
17. Use of the recombinant chimera proteins, LacZ-Env and Gag-Env, for immunological studies on HIV-1 infection.
Morimoto M; Saitoh A; Ueba N; Nakata A; Shinagawa H
AIDS Res Hum Retroviruses; 1993 Oct; 9(10):971-8. PubMed ID: 7506555
[TBL] [Abstract][Full Text] [Related]
18. Highly immunoreactive antigenic site in a hydrophobic domain of HIV-1 gp41 which remains undetectable with conventional immunochemical methods.
Närvänen A; Korkolainen M; Kontio S; Suni J; Turtianen S; Partanen P; Soos J; Vaheri A; Huhtala ML
AIDS; 1988 Apr; 2(2):119-23. PubMed ID: 3132938
[TBL] [Abstract][Full Text] [Related]
19. Reliable confirmation and quantitation of human immunodeficiency virus type 1 antibody using a recombinant-antigen immunoblot assay.
Busch MP; el Amad Z; McHugh TM; Chien D; Polito AJ
Transfusion; 1991 Feb; 31(2):129-37. PubMed ID: 1899951
[TBL] [Abstract][Full Text] [Related]
20. [Detection of antibodies against HIV-1 and HIV-2 using "new antigens"].
Miyakoshi H
Nihon Rinsho; 1993 Sep; 51 Suppl():279-83. PubMed ID: 7505848
[No Abstract] [Full Text] [Related]
[Next] [New Search]
